Pharma Pioneer

Triumvira Begins Phase I/II Trial for TAC101-CLDN18.2 Solid Tumor Therapy

31 May 2024
3 min read

In a recent development, Triumvira Immunologics, a company specializing in the creation of innovative T cell therapies for solid tumor treatment, has reached a significant milestone. The clinical-stage firm has commenced dosing for the first patient in its TACTIC-3 trial, a Phase I/II clinical study (NCT05862324). This study is focused on evaluating the safety and effectiveness of TAC101-CLDN18.2, an advanced cell therapy that utilizes genetically modified autologous T cells. These cells are engineered to express a T-cell Antigen Coupler (TAC), which targets Claudin 18.2, a protein that is overexpressed in various solid tumors, notably gastric cancer.

Dr. Andreas Bader, Chief Scientific Officer at Triumvira, highlighted Claudin 18.2 as an ideal target for cell therapy due to its limited presence in normal tissues and its heightened expression in certain cancer types. The company's Chief Medical Officer, Dr. Deyaa Adib, expressed enthusiasm about the potential of TAC101-CLDN18.2 to fill a significant therapeutic void for solid tumors, particularly for those that are Claudin 18.2 positive. The therapy is anticipated to be beneficial for patients with gastric, lung, ovarian, and pancreatic cancers, where there is currently a lack of approved treatments against Claudin 18.2.

The TACTIC-3 study is designed to assess the safety profile, determine the recommended Phase II dose, and analyze the pharmacokinetic behavior and efficacy of TAC101-CLDN18.2 in patients who have undergone a minimum of two prior treatments. For patients with pancreatic ductal adenocarcinoma, the study allows for inclusion based on one prior line of antineoplastic therapy. Eligibility also extends to subjects undergoing current therapies without demonstrated benefits, provided there was no measurable disease at the study's outset.

Triumvira Immunologics is recognized for its pioneering work in T cell therapies, utilizing its proprietary TAC technology to activate T cell functions in a manner distinct from other therapies like CAR-T and engineered TCR therapies. The company's goal is to develop clinically safe and effective treatments that can be re-administered as needed. In addition to Claudin 18.2, Triumvira is targeting other tumor-associated antigens such as HER2, GUCY2C, and GPC3. The company operates from locations in San Diego, Austin, Texas, and Hamilton, Ontario.
How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Neuroinflammation: Alzheimer's Promising Treatment Target
Pharma Pioneer
3 min read
Neuroinflammation: Alzheimer's Promising Treatment Target
31 May 2024
In the early 20th century, Alois Alzheimer identified neuroinflammation as a factor in the disease now named after him, noting the presence of microglia cells in his initial sketches.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - May 30
Pharma Frontiers
12 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - May 30
30 May 2024
May 30th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
TILT Biotherapeutics Shares Clinical Results of TILT-123 for Ovarian Cancer at ASCO 2024
Latest Hotspot
3 min read
TILT Biotherapeutics Shares Clinical Results of TILT-123 for Ovarian Cancer at ASCO 2024
30 May 2024
TILT Biotherapeutics' one abstract highlights encouraging safety and efficacy findings of TILT-123 in patients with ovarian cancer.
Read →
selectION Announces Phase 1b Trial Start for si-544 in Psoriasis Vulgaris and Psoriatic Arthritis Patients
Latest Hotspot
3 min read
selectION Announces Phase 1b Trial Start for si-544 in Psoriasis Vulgaris and Psoriatic Arthritis Patients
30 May 2024
selectION, Inc. declared the commencement of a Phase 1b study involving its leading candidate si-544 in adult individuals suffering from psoriasis vulgaris or psoriatic arthritis.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.